Journal ArticleCrit Care Med · July 1, 2021
OBJECTIVES: Four peer-reviewed publications have reported results from randomized controlled trials of convalescent plasma for coronavirus disease 2019 infection; none were conducted in the United States nor used standard plasma as a comparator. To determi ...
Full textLink to itemCite
Book · November 2020
In addition, "ABC-PICU," which examined the age of red cells on outcomes in critically ill children, is discussed in this edition. The latest information on the use of pathogen-inactivated blood products is also included"-- ...
Cite
Journal ArticleAnn Clin Lab Sci · July 2020
OBJECTIVE: While lookback investigations follow specific Food and Drug Administration (FDA) requirements, the management of blood product market withdrawals from suppliers varies widely. Follow-up data are limited, prompting this analysis of the types and ...
Link to itemCite
Journal ArticleJAMA · December 10, 2019
IMPORTANCE: The clinical consequences of red blood cell storage age for critically ill pediatric patients have not been examined in a large, randomized clinical trial. OBJECTIVE: To determine if the transfusion of fresh red blood cells (stored ≤7 days) red ...
Full textLink to itemCite
Journal ArticleTransfusion · March 2017
BACKGROUND: Randomized trials, for example, RECESS, comparing "young" (median, 7-day) versus "middle-aged" (median, 28-day) red blood cells (RBCs), showed no difference in outcome. These data are important; however, they do not inform us about the safety a ...
Full textLink to itemCite
Journal ArticleTransfusion · July 2016
BACKGROUND: Recent animal studies suggest that transfusion of plasma from young donors reverses age-related neurologic and cardiac changes in older recipients. Associations between age of blood product donors and corresponding outcomes in recipients have n ...
Full textLink to itemCite
Journal ArticleTransfusion · October 2014
BACKGROUND: Pretransfusion washing of red blood cells (RBCs) stored for a longer duration may have theoretical advantages but few data exist to support this practice. In many hospital settings, use of a point-of-care cell washer could conceivably be used t ...
Full textLink to itemCite
Journal ArticleJ Clin Apher · June 2014
The American Society for Apheresis (ASFA) conducted a 1 day consensus conference on Thrombotic Thrombocytopenic Purpura (TTP) during its annual meeting in Atlanta, GA, on April 10, 2012. The authors of this article, a subcommittee of ASFA's Clinical Applic ...
Full textLink to itemCite
Journal ArticleEarly Hum Dev · May 2014
AIMS: The objective of this study is to determine the incidence of and risk factors for necrotizing enterocolitis (NEC) and transfusion-associated NEC (TANEC) in very-low-birth-weight (VLBW) infants pre/post implementation of a peri-transfusion feeding pro ...
Full textLink to itemCite
Journal ArticleTransfusion · May 2014
BACKGROUND: Intraoperative autologous platelet (PLT) collection as part of a multimodal blood conservation program carries a Class IIa recommendation from the Societies of Thoracic Surgeons and Cardiovascular Anesthesiologists, but achieving a suitable PLT ...
Full textLink to itemCite
Journal ArticleTransfusion · November 2012
BACKGROUND: Stored red blood cells (RBCs) accumulate biochemical and biophysical changes. Maximum storage duration is based on acceptable in vitro characteristics and 24-hour survival, but not RBC function. Relatively little is known about the impact of RB ...
Full textLink to itemCite
Journal ArticleSemin Thromb Hemost · November 2012
Thienopyridine-derivatives (ticlopidine, clopidogrel, and prasugrel) are the primary antiplatelet agents. Thrombotic thrombocytopenic purpura (TTP) is a rare drug-associated syndrome, with the thienopyridines being the most common drugs implicated in this ...
Full textLink to itemCite
Journal ArticlePerfusion · July 2011
A 4.3 kg, three-month-old patient, diagnosed with a perimembranous ventricular septal defect, presented for cardiac surgery. Upon initiation of cardiopulmonary bypass (CPB), the patient developed carboxyhemoglobinemia (11.1%). Potential sources for the une ...
Full textLink to itemCite
Book · 2011
New this edition: * Component discussion addresses two recently approved platelet products. * Expanded information on prothrombin complex concentrates. * Revamped discussion of massive transfusion. * Expanded information on anticoagulant ... ...
Cite
Journal ArticleJ Thorac Cardiovasc Surg · December 2010
OBJECTIVE: Pulmonary dysfunction is common in transfused patients recovering from heart surgery. Plasma transfusion from female donors has been linked with rare catastrophic lung injury, but its relationship with outcome after cardiac surgery is poorly und ...
Full textLink to itemCite
Journal ArticleTransfusion · November 2010
Featured Publication
BACKGROUND: Red blood cell (RBC) transfusion is common during cardiac surgical procedures. Empiric crossmatching, without attempting to estimate individual transfusion requirements is typical. We hypothesized that a clinical prediction tool could be develo ...
Full textLink to itemCite
Journal ArticleAm J Clin Pathol · November 2010
Platelet factor 4 (PF4)/heparin antibody, typically associated with heparin therapy, is reported in some heparin-naive people. Seroprevalence in the general population, however, remains unclear. We prospectively evaluated PF4/heparin antibody in approximat ...
Full textLink to itemCite
Journal ArticleExpert Rev Hematol · October 2010
Featured Publication
Transfusion-related acute lung injury (TRALI) has been identified as the most common cause of transfusion-related death. Although extensive literature supports restrictions on female-donor plasma to reduce antibody-mediated TRALI, only a few outcome studie ...
Full textLink to itemCite
Journal ArticleJ Clin Apher · 2010
Featured Publication
The American Society for Apheresis (ASFA) Apheresis Applications Committee is charged with a review and categorization of indications for therapeutic apheresis. Beginning with the 2007 ASFA Special Issue (fourth edition), the subcommittee has incorporated ...
Full textLink to itemCite
Journal ArticleTransfusion · July 2009
Featured Publication
BACKGROUND: Recent evidence demonstrates an association between duration of storage of red blood cells (RBC) and morbidity and mortality after cardiac surgery. We studied the feasibility of two different schemes for categorizing and randomizing age of RBC ...
Full textLink to itemCite
Journal ArticleKidney Int Suppl · February 2009
Featured Publication
Thrombotic thrombocytopenic purpura (TTP) is a fulminant disease characterized by platelet aggregates, thrombocytopenia, renal insufficiency, neurologic changes, and mechanical injury to erythrocytes. Most idiopathic cases of TTP are characterized by a def ...
Full textLink to itemCite
Journal ArticleAIDS · June 19, 2008
OBJECTIVES: Valproic acid and intensified antiretroviral therapy may deplete resting CD4+ T-cell HIV infection. We tested the ability of valproic acid to deplete resting CD4+ T-cell infection in patients receiving standard antiretroviral therapy. METHODS: ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · September 18, 2007
OBJECTIVES: We sought to describe clinical and laboratory findings for a large cohort of patients with thienopyridine-associated thrombotic thrombocytopenic purpura (TTP). BACKGROUND: The thienopyridine derivatives, ticlopidine and clopidogrel, are the 2 m ...
Full textLink to itemCite
Journal ArticleJ Clin Apher · June 2007
The American Society for Apheresis (ASFA) Committee on Clinical Applications systematically and critically reviews published information on the use of therapeutic apheresis in clinical practice. On the basis of this review, selected diseases are assigned o ...
Full textLink to itemCite
Journal ArticleJ Clin Apher · June 2007
The American Society for Apheresis (ASFA) Apheresis Applications Committee is charged with a review and categorization of indications for therapeutic apheresis. This elaborate process had been undertaken every 7 years resulting in three prior publications ...
Full textLink to itemCite
Journal ArticleJ Clin Apher · June 2007
The American Society for Apheresis (ASFA) Apheresis Applications Committee is responsible for a review and categorization of indications for therapeutic apheresis. The results of the review process were previously published in 1986, 1993, and 2000 as the A ...
Full textLink to itemCite
Journal ArticleTransfusion · April 2007
Featured Publication
BACKGROUND: Previously, cryopreserved red blood cell (RBC) units derived from CPD/AS-5 whole-blood (WB) collections have been limited to 24 hours postthaw storage (1-6 degrees C). STUDY DESIGN AND METHODS: Sixty-four leukoreduced (LR) and 54 nonleukoreduce ...
Full textLink to itemCite
Journal ArticleTransfus Apher Sci · February 2007
This article reviews numerous multi-center clinical trials, either ongoing or in planning stages, which involve diverse clinical applications and emerging technologies in apheresis and transfusion medicine. The investigations summarized herein involve the ...
Full textLink to itemCite
Journal ArticleTher Apher Dial · June 2006
Featured Publication
For thrombotic thrombocytopenic purpura (TTP), daily plasma exchange (TPE) is typically discontinued when the platelet count normalizes (>150 x 10(9)/L). We observed a decline in platelet count during TPE and in patients who appeared pseudo-refractory beca ...
Full textLink to itemCite
Journal ArticleImmunohematology · 2006
Featured Publication
The University of North Carolina at Chapel Hill (UNC) is a tertiarycare, academic university hospital and a major referral center for patients across the state of North Carolina. This 700-bed, Level 1 trauma center transfuses more than 22,000 RBC units to ...
Link to itemCite
Journal ArticleSemin Thromb Hemost · December 2005
The recurrence of thrombotic thrombocytopenic purpura (TTP) in 20 to 50% of patients who survive their initial episode, is not only a challenge to manage clinically, but brings to light our lack of understanding of the underlying pathophysiology. Recurrenc ...
Full textLink to itemCite
Journal ArticleTransfusion · September 2005
BACKGROUND: Treatment of thrombotic thrombo-cytopenia purpura (TTP) with daily therapeutic plasma exchange (TPE) may be accompanied by a variety of adjunctive interventions including most recently rituximab. Rituximab, a murine and human monoclonal antibod ...
Full textLink to itemCite
ConferenceBlood · November 16, 2004
AbstractBackground: Due to the rarity of TTP (approximately 4 cases per million), epidemiologic data and correlative laboratory samples from a prospectively identified incident cohort of TTP patients are nee ...
Full textCite
ConferenceBlood · November 16, 2004
AbstractIntroduction: The antiplatelet agents ticlopidine and clopidogrel are thienopyridine derivatives that are commonly used for secondary prevention of cerebrovascular events, prevention of coronary arte ...
Full textCite
Journal ArticleTransfusion · November 2004
BACKGROUND: The utilization of cryopreserved red blood cell (RBC) units had been limited by a maximum postdeglycerolization storage of 24 hours at 1 to 6 degrees C until the recent development of a closed system for the glycerolization and deglycerolizatio ...
Full textLink to itemCite
Journal ArticleStroke · February 2004
BACKGROUND AND PURPOSE: Since the 1999 identification of clopidogrel-associated thrombotic thrombocytopenic purpura (TTP) through independent active surveillance, subsequent cases have been identified by pharmaceutical suppliers of clopidogrel and the Food ...
Full textLink to itemCite
Journal ArticleJ Clin Apher · 2004
Thrombotic microangiopathy (TMA) is a recognized complication of malignant hypertension (HTN). Such patients have blood pressures > or = 200/140 mmHg but the condition is defined by the presence of papilledema and is frequently complicated by acute renal f ...
Full textLink to itemCite
Journal ArticleTransfus Apher Sci · April 2003
The clinical applications of therapeutic apheresis (TA) encompass a broad spectrum. Diversity exists not only in the age and acuity of patients treated, but also in the range of therapeutic approaches and technology. Particularly over the past decade, ther ...
Full textLink to itemCite
Journal ArticleTransfusion · November 2001
BACKGROUND: A novel apheresis procedure for a blood separator (MCS+, Haemonetics) enables the collection of 2 WBC-reduced RBC units in a single donation by using one disposable set with one in-line WBC-reduction filter (RC2H, Pall Corp.). The objective of ...
Full textLink to itemCite
Journal ArticleImmunohematology · 2001
Information on the gene frequencies of the Rh system in the Mexican or Mexican American population is currently not available in the medical literature, thus hindering management of pregnancies at risk for development of hemolytic disease of the newborn. D ...
Link to itemCite
Journal ArticleJ Clin Apher · 2001
Plasma replacement for thrombotic thrombocytopenic purpura (TTP) is accomplished with various plasma products. This study sought to determine the incidence of allergic reactions with FFP or CPP as replacement in therapeutic plasma exchange (TPE). Forty-one ...
Full textLink to itemCite
Journal ArticleTher Apher · February 1999
Endeavors to optimize the management of thrombotic thrombocytopenic purpura (TTP) syndrome and improve mortality and relapse rates are hindered by its poorly understood pathophysiology. Variability in the application of therapeutic plasma exchange (TPE), i ...
Full textLink to itemCite
Journal ArticleAm J Clin Pathol · June 1998
The maximum storage time for platelet concentrates is 5 days, owing to the higher risk bacterial contamination with longer storage. The expiration date could potentially be extended if a rapid system to detect microbial contamination or a safe sterilizatio ...
Full textLink to itemCite
Journal ArticleTransfusion · May 1998
BACKGROUND: The etiology of thrombotic thrombocytopenic purpura (TTP) remains undetermined. TTP has been associated with a number of secondary causes including infections, drugs, menses, pregnancy, autoimmune diseases, and bone marrow transplantation. Rega ...
Full textLink to itemCite
Journal ArticleJ Clin Apher · 1998
Featured Publication
Thrombotic thrombocytopenic purpura (TTP) remains enigmatic from the perspective of its etiology, pathophysiology, and treatment. Once recognized, the accepted standard of care for TTP is daily therapeutic plasma exchange (TPE). However, the diversity in T ...
Full textLink to itemCite
Journal ArticleJ Clin Apher · 1998
Elevated serum lactate dehydrogenase (LDH) is a characteristic finding in patients with thrombotic thrombocytopenic purpura (TTP). It is widely accepted that total serum LDH principally rises due to the release of red blood cell LDH as a consequence of int ...
Full textLink to itemCite
Journal ArticleJ Clin Apher · 1997
Today, albumin, or a combination of saline and albumin, is used and widely accepted as a replacement for routine plasma exchange. However, decreased availability (due to market recalls secondary to Creutzfeld-Jacob or bacterial contamination risk) rising c ...
Full textLink to itemCite
Journal ArticleClin Lab Med · December 1996
Recent advances in apheresis have emerged in a variety of clinical settings. Improvements in granulocyte and peripheral blood stem cell collection and mobilization, the changing role of intravenous gamma globulin, the importance of patient assessment and s ...
Link to itemCite
Journal ArticleLab Invest · November 1996
Tissue transglutaminase (tTG) is postulated to play a role in apoptosis, cell adhesion, metastasis, and extracellular matrix (ECM) assembly. In this study, the distribution and expression of tissue transglutaminase was investigated in normal human mammary ...
Link to itemCite
Journal ArticleAnn Surg · April 1994
OBJECTIVE: Overexpression of the p53 and HER-2/neu oncogenes are the two most common genetic abnormalities associated with breast cancer. Shorter survival time has been reported in patients with tumors with p53 or HER-2/neu. This report analyzes a retrospe ...
Full textLink to itemCite